Cargando…
Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
Factor replacement therapy for the treatment of moderate to severe haemophilia A and B can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor IX. Treatment with the nanofiltered anti-inhibitor coagulant complex, Factor Eight Inhibitor Bypassing Activity (F...
Autores principales: | Antunes, S V, Tangada, S, Stasyshyn, O, Mamonov, V, Phillips, J, Guzman-Becerra, N, Grigorian, A, Ewenstein, B, Wong, W-Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216433/ https://www.ncbi.nlm.nih.gov/pubmed/23910578 http://dx.doi.org/10.1111/hae.12246 |
Ejemplares similares
-
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery
por: Pabinger, Ingrid, et al.
Publicado: (2021) -
Combination of Novoseven and Feiba in Hemophiliac Patients with Inhibitors
por: Malkan, Umit Yavuz, et al.
Publicado: (2018) -
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
por: Ettingshausen, Carmen Escuriola, et al.
Publicado: (2023) -
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
por: VALENTINO, L A, et al.
Publicado: (2012) -
Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)
por: Negrier, Claude, et al.
Publicado: (2016)